The Effects of SB1518, a Novel Oral JAK2 Inhibitor, On Ex Vivo Expanded PV Erythroid Progenitors Correlate with Clinical Observations

被引：0
|
作者：
Goh, Kee Chuan [1 ]
Hart, Stefan [1 ]
Tan, Yong Cheng [1 ]
Chithra, Amalini [1 ]
Ong, Kiat H. [2 ]
Wood, Jeanette
机构：
[1] S BIO PTE LTD, Biol, Singapore, Singapore
[2] Tan Tock Seng Hosp, Dept Lab Med, Singapore, Singapore
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1138 / 1138
页数：1
相关论文
共 24 条
  • [1] FIRST REPORT OF THE PHASE-I STUDY OF THE NOVEL ORAL JAK2 INHIBITOR SB1518 IN PATIENTS WITH MYELOFIBROSIS
    Seymour, F.
    To, B.
    Goh, A.
    Meadows, L.
    Ethirajulu, A.
    Wood, A.
    Zhu, A.
    Roberts, W.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 472 - 472
  • [2] SB1518, a novel JAK2/FLT3 inhibitor for the treatment of myeloid malignancies
    Hart, Stefan
    Goh, Kee Chuan
    Novotny-Diermayr, Veronica Veronica
    Tan, Yong Cheng
    Madan, Babita
    Amalini, Chithra
    Loh, Yung Kiang
    Ong, Lai Chun
    Williams, Anthony
    Lee, Angeline
    Poulsen, Anders
    Jayaraman, Ramesh
    Ethirajulu, Kantharaj
    Dymock, Brian W.
    Wood, Jeanette M.
    CANCER RESEARCH, 2011, 71
  • [3] Phase II study of SB1518, an orally available novel JAK2 inhibitor, in patients with myelofibrosis
    Deeg, H. J.
    Odenike, O.
    Scott, B. L.
    Estrov, Z.
    Cortes, J. E.
    Thomas, D. A.
    Zhu, H. J.
    Kantarjian, H.
    Verstovsek, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies
    Hart, S.
    Goh, K. C.
    Novotny-Diermayr, V.
    Hu, C. Y.
    Hentze, H.
    Tan, Y. C.
    Madan, B.
    Amalini, C.
    Loh, Y. K.
    Ong, L. C.
    William, A. D.
    Lee, A.
    Poulsen, A.
    Jayaraman, R.
    Ong, K. H.
    Ethirajulu, K.
    Dymock, B. W.
    Wood, J. W.
    LEUKEMIA, 2011, 25 (11) : 1751 - 1759
  • [5] The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML
    V Novotny-Diermayr
    S Hart
    K C Goh
    A Cheong
    L-C Ong
    H Hentze
    M K Pasha
    R Jayaraman
    K Ethirajulu
    J M Wood
    Blood Cancer Journal, 2012, 2 : e69 - e69
  • [6] SB1518: A potent and orally active JAK2 inhibitor for the treatment of myeloproliferative disorders.
    Goh, Kee C.
    Ong, Wai C.
    Hu, Changyong
    Hentze, Harries
    Liang, Ai L.
    Stunkel, Walter
    Tan, Yong C.
    Sangthongpitag, Kanda
    Goh, Siok K.
    Sieh, Shirly
    Bonday, Zahid Q.
    William, Anthony D.
    Lee, Angeline
    Llanchard, Stephanie
    Liu, Te C.
    Sattler, Martin
    Griffin, James D.
    Dymock, Brian W.
    Kantharaj, Ethirajulu
    Wood, Jeanette M.
    BLOOD, 2007, 110 (11) : 165A - 166A
  • [7] The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML
    Novotny-Diermayr, V.
    Hart, S.
    Goh, K. C.
    Cheong, A.
    Ong, L-C
    Hentze, H.
    Pasha, M. K.
    Jayaraman, R.
    Ethirajulu, K.
    Wood, J. M.
    BLOOD CANCER JOURNAL, 2012, 2 : e69 - e69
  • [8] SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies
    S Hart
    K C Goh
    V Novotny-Diermayr
    C Y Hu
    H Hentze
    Y C Tan
    B Madan
    C Amalini
    Y K Loh
    L C Ong
    A D William
    A Lee
    A Poulsen
    R Jayaraman
    K H Ong
    K Ethirajulu
    B W Dymock
    J W Wood
    Leukemia, 2011, 25 : 1751 - 1759
  • [9] PHASE 1 STUDY OF A NOVEL ORAL JAK2 INHIBITOR, SB1518, IN PATIENTS WITH RELAPSED LYMPHOMA: EVIDENCE OF CLINICAL AND BIOLOGIC ACTIVITY IN MULTIPLE LYMPHOMA SUBTYPES
    Younes, A.
    Fanale, M.
    Mclaughlin, P.
    Copeland, A.
    Faria, S. De Castro
    Zhu, J.
    ANNALS OF ONCOLOGY, 2011, 22 : 136 - 137
  • [10] Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia
    Hart, S.
    Goh, K. C.
    Novotny-Diermayr, V.
    Tan, Y. C.
    Madan, B.
    Amalini, C.
    Ong, L. C.
    Kheng, B.
    Cheong, A.
    Zhou, J.
    Chng, W. J.
    Wood, J. M.
    BLOOD CANCER JOURNAL, 2011, 1 : e44 - e44
123